In contrast, according to the COMPASS (Comprehensive Molecular Characterization of Advanced Pancreatic Ductal Adenocarcinoma for Better Treatment Selection, NCT02750657) trial [64] and other studies [59], squamous PDAC is a more aggressive tumor subtype that is less sensitive to first-line adjuvant chemotherapy based on FOLIFIRNOX [55,105], 5-FU, oxaliplatin [92], or isolated leucovorin [66], as well as combined (or not) MEK and EGFR inhibitors [46,86]. Here, EGFR is linked to neoplasm.